Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Incannex Healthcare Limited
Incannex Healthcare Limited News
Jul 31, 2025 - globenewswire.com
Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term
Jul 30, 2025 - globenewswire.com
Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X
Jul 25, 2025 - globenewswire.com
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo
Jun 24, 2025 - globenewswire.com
Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch
Incannex Healthcare Limited Quantitative Score
About Incannex Healthcare Limited
Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's products include IHL-42X, which is in Phase II clinical trials for obstructive sleep apnea; IHL-216A for traumatic brain injury; and IHL-675A, a combination of hydroxychloroquine and cannabidiol for the prevention and treatment of inflammatory lung conditions, such as acute respiratory distress syndrome, chronic obstructive pulmonary disease, asthma, and bronchitis, as well as rheumatoid arthritis and inflammatory bowel diseases. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea; and Monash Trauma Group at the Department of Neuroscience, Monash University to conduct a study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited was incorporated in 2001 and is based in Sydney, Australia.
Incannex Healthcare Limited Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Incannex Healthcare Limited Financials
Table Compare
Compare IXHL metrics with: | |||
|---|---|---|---|
Earnings & Growth | IXHL | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | IXHL | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | IXHL | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | IXHL | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Incannex Healthcare Limited Income
Incannex Healthcare Limited Balance Sheet
Incannex Healthcare Limited Cash Flow
Incannex Healthcare Limited Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Neutral |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Incannex Healthcare Limited Executives
| Name | Role |
|---|---|
| Mr. Joel Bradley Latham | President, Chief Executive Officer & Executive Director |
| Mr. Lekhram Changoer M.Sc. | Chief Technology Officer & Member of Advisory Board |
| Mr. Joseph Swan | Chief Financial Officer, Treasurer & Secretary |
| Natalie May | Head of Clinical Operations |
| Dr. Luigi M. Barbato M.D. | Chief Medical Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Joel Bradley Latham | President, Chief Executive Officer & Executive Director | Male | 1990 | 704.07K |
| Mr. Lekhram Changoer M.Sc. | Chief Technology Officer & Member of Advisory Board | Male | 1967 | 137.65K |
| Mr. Joseph Swan | Chief Financial Officer, Treasurer & Secretary | Male | 1992 | 134.81K |
| Natalie May | Head of Clinical Operations | -- | ||
| Dr. Luigi M. Barbato M.D. | Chief Medical Officer | -- |
Incannex Healthcare Limited Insider Trades
| Date | 23 Oct |
| Name | Barbato Luigi M. |
| Role | Chief Medical Officer |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 100476 |
| Date | 21 Oct |
| Name | Barbato Luigi M. |
| Role | Officer |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 30 Jun |
| Name | Swan Joseph |
| Role | Officer |
| Transaction | Disposed |
| Type | |
| Shares | 0 |
| Date | 21 Dec |
| Name | Valentine Troy |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 670000 |
| Date | 21 Dec |
| Name | Widdows Peter |
| Role | Director |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 100000 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 23 Oct | Barbato Luigi M. | Chief Medical Officer | Acquired | A-Award | 100476 |
| 21 Oct | Barbato Luigi M. | Officer | Disposed | 0 | |
| 30 Jun | Swan Joseph | Officer | Disposed | 0 | |
| 21 Dec | Valentine Troy | Director | Acquired | A-Award | 670000 |
| 21 Dec | Widdows Peter | Director | Acquired | A-Award | 100000 |